НОВАЯ КОРОНАВИРУСНАЯ БОЛЕЗНЬ (COVID-19) И СЕРДЕЧНО- СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ

В обзоре представлены актуальные проблемы сочетания новой коронавирусной инфекции COVID-19 и сердечно-сосудистых заболеваний. Обсуждаются результаты немногочисленных клинических исследований и отдельных клинических случаев, иллюстрирующих сложности ведения пациентов с вирусной инфекцией и сопутствующей патологией. Обозначены данные по лекарственным взаимодействиям антивирусных и сердечно-сосудистых препаратов. Представлены возможные клинические картины наиболее типичных сочетаний распространенных сердечно-сосудистых заболеваний и COVID-19. Выделены пациенты группы риска с необходимостью оказания интенсивной лечебно-диагностической помощи во избежание неблагоприятного исхода коморбидности.

1. Guan W.J., Ni Z.Y, Hu Y, Liang W., Ou Ch., He J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 2020 Feb 28. doi: 10.1056/NEJMoa2002032.

2. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16-24 February 2020. Available at: https ://wwwwhoint/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-reportpdf. (accessed March 9, 2020.

3. Шляхто Е. В., Конради А. О., Арутюнов Г. П., Арутюнов А. Г, Баутин А. Е., Бойцов С. А., Виллевальде С. В., Григорьева Н. Ю., Дупляков Д. В., Звартау Н. Э., Козиолова Н. А., Лебедев Д. С., Мальчикова С. В., Медведева Е. А., Михайлов Е. Н., Моисеева О. М., Орлова Я. А., Павлова Т. В., Певзнер Д. В., Петрова М. М., Ребров А. П., Ситникова М. Ю., Соловьева А. Е., Тарловская Е. И., Трукшина М. А., Федотов П. А., Фомин И. В., Хрипун А. В., Чесникова А. И., Шапошник И. И., Явелов И. С., Яковлев А. Н. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi: 10.15829/1560-4071-2020-3-3801.

4. Driggin E., Madhavan M.V, Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G. et al Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020 Mar 19. Epublished Doi:10.1016/jjacc.2020.03.031.

5. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Yu. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 Mar 11; 1-8 doi: 10.1007/s00392-020-01626-9

6. Wu Z., Mc Googan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. Feb 24. doi: 10.1001/jama.2020.2648.

7. Porcheddu R., Serra C., Kelvin D., Kelvin N., Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14:125-128. doi: 10.3855/jidc.12600.

8. Chen N., Zhou M., Dong X., Qu J., Gong F., Ya. Han et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513. doi: 10.1016/S0140-6736(20)30211-7.

9. Liu W.M., Vander Zeijst B.A., Boog C.J., Soethout E.C. Aging and impaired immunity to influenza viruses: implications for vaccine development. HumVaccin. 2011; 7 Suppl: 94-8.

10. Zidar D.A., Al-Kindi S.G., Liu Y, Krieger N.I., Perzynski A.T., Osnard M. et al. Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. JAMA. Netw Open 2019;2:e1916526 doi: 10.1001/jamanetworkopen.2019.16526.

11. Saltiel A.R., Olefsky J.M. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127:1-4

12. Akhmerov A., Marban E. COVID-19 and the Heart. Circulation. 2020Apr 11. doi: 10.1161/CIRCRESAHA.120.317055.

13. Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasonit D. et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; DOI: 10.1001/jamacardio.2020.1096.

14. ZhengY.-Y, MaY-T., Zhang J.-Y, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020. Mar 5. doi: 10.1038/s41569-020-0360-5.

15. Ganatra S., Hammond S.P., Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer JACC: Cardio Oncology. 2020. doi: 10.1016/j.jaccao.2020.03.001.

16. Mortality G.B.D., Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-1544.

17. Liang W., Guan W., Chen Retal. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335-337.

18. Guo T., FanY, Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMACardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1017.

19. Sharon E. Fox, Aibek Akmatbekov, Jack L. Harbert, Guang Li, J. Quincy Brown, Richard S. Vander Heide. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. medRxiv. https://www.medrxiv.org/content/10.1101/2020.04.06.20050575v1/doi:https://doi.org/10.1101/2020.04.06.20050575.

20. Welt F.G.P., Shah P.B., Aronow H.D., Bortnick A.E., Henry T.D., Sherwood M.W., Young M.N., Davidson L.J., Kadavath S., Mahmud E., Kirtane A.J., American College of Cardiology’s (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI), Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI. J Am Coll Cardiol. 2020 Mar 16; S0735-1097(20)34566-6. doi: 10.1016/j.jacc.2020.03.021..

21. Bettari L., Pero G., Maiandi C., Messina A., Saccocci M., Cirillo M., Troise G., Conti E., Cuccia C., Maffeo D. Exploring personal protection during high-risk PCI in a COVID-19 patient -Impella CP mechanicalsupportduring ULMCA bifurcationstenting. JACC: CaseReports. April 2020 DOI:10.1016/j.jaccas.2020.03.006.

22. Fried J.A., Ramasubbu K., Bhatt R., Topkara V.K., Clerkin K.J., Horn E. et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.

23. Juneman E. Leading the compassionate charge. Circ Heart Fail. 2020 Apr;13(4):e007085. doi: 10.1161/CIRCHEARTFAILURE.120.007085.

24. Oudit G. Y, Kassiri Z., Jiang C., Liu P.P., Poutanen S.M., Penninger J.M., Butany J. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS Eur J Clin Invest. 2009 Jul; 39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x.

25. Haeck G., Ancion A., Marechal P., Oury C., Lancellotti P. COVID-19 andcardiovascular diseases. Rev Med Liege. 2020 Apr;75(4):226-232.

26. Huang C., Wang Y, Li X., Ren L., Zhao J., Hu Y, Zhang L., Fan G., Xu J., Gu X. et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

27. Wang D. , Hu B. , Hu C., Zhu F. , Liu X. , Zhang J. , et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585.

28. Dong N., Cai J., Zhou Y, Liu J., Li F., End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV, JACC Heart Fail. 2020 Apr 7. pii: S2213-1779(20)30200-6. doi: 10.1016/j.jchf.2020.04.001.

29. Sakabe M., Yoshioka R., Fujiki A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J. Cardiol. Cases. 2013 Oct 29;8(6): 173175. doi: 10.1016/j.jccase.2013.08.002.

30. Al Ghamdi M., Mushtaq F., Awn N., Shalhoub S. MERS CoV Infection in Two Renal Transplant Recipients: Case Report. Am J Transplant. 2015;15:1101-1104.

31. Kumar D., Tellier R., Draker R., Levy G., Humar A. Severe Acute Respiratory Syndrome (SARS) in a Liver Transplant Recipient and Guidelines for Donor SARS Screening. Am J Transplant. 2003;3:977-981.

32. Li F., Cai Jand Dong N. First Cases of COVID-19 in Heart Transplantation From China. J Heart Lung Transplant. 2020. doi: 10.1016/j.healun.2020.03.006.

33. Ren Z.-Li, Hu R., Wang Z.-W., Zhang M., Ruan Y-L., Wu Z.-Y. et al Epidemiological and Clinical Characteristics of Heart Transplant Recipients During the 2019 Coronavirus Outbreak in Wuhan, China: A Descriptive Survey Report. J Heart Lung Transplant. 2020. doi: 10.1016/j.healun.2020.03.008.

34. Guidance for Cardiothoracic Transplant and Mechanical Circulatory Support Centers regarding SARS CoV-2 infection and COVID-19: March 17, 2020. Available at: https://community.ishlt.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=afb06f06-5d63-13d4-c107-d152a9f6cd46.( accessed 13.03.2020)

35. American Society of Transplantation. 2019-nCoV (Coronavirus): FAQs for Organ Transplantation. Updated Feb 29, 2020. Available at: https://www.myast.org/sites/default/files/COVID19%20FAQ%20Tx%20Centers%20030220-1.pdf (accessed 13.03.2020)

36. Prognostic Factors in COVID-19 Patients Complicated With Hypertension (NCT04272710) Available at: https://clinicaltrials.gov/ct2/show/NCT04292964.accessed (14.03.2020)

37. 7. Kuster G.M., Pfister O., Burkard T., Zhou Q., Twerenbold R., Haaf Ph., Widmer A.F., Osswald S. SARS-CoV2: should inhibitors of the renin-angiotensin system be with drawn in patients with COVID-19? European Heart Journal. 2020 doi: 10.1093/eurheartj/ehaa235.

38. University of Liverpool. Interactions with Experimental COVID-19 Therapies. Available at: https://www.Covid19-druginteractions.org (accessed 13.04.2020)

39. Virani S.S. Is There a Role For Statin Therapy in Acute Viral Infections? Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/09/is-there-a-role-for-statin-therapy-in-acute-viral-infections-covid-19. (accessed 14.04.2020)

40. Liu W., Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism Available at: https://chemrxiv.org (accessed 14.04.2020)

41. Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., Clark C., Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 25 March 25. doi:10.11n/JTH.14810.

42. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 Mar 27. doi: 10.1m/jth.14817.

43. Hunt B., Retter A., McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. Available at: https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf (accessed 14.04.2020.)

44. COVID-19 Clinical Guidance For the Cardiovascular Care Team. ACC CLINICAL BULLETIN. https://www.acc.org/latest-in-cardiology/features/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf. (accessed 13.04.2020)